RxDoctor Payments Data

Khaled Abdeljawad, MD

Gastroenterology · Indianapolis, INNPI 1285947416

Payments from drug & device makers

$1,875in general payments, 2019–2025

Across 59 payments — averaging $31.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$842
  • Johnson & Johnson$357
  • Bristol Myers Squibb$227
  • Pfizer$164
  • Braintree Laboratories, Inc.$99
  • Lilly USA, LLC$71
  • plus $115 from 3 others

What the payments were for

  • Food & beverage$1,68090%
  • Education$965%
  • Gifts$995%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,875 in reported general payments places this provider in the 45th percentile of 323 gastroenterology providers in Indiana.

See all gastroenterology providers in Indiana

Medicare billing

Part B allowed, 2024
$38,510
Medicare patients
205
Services billed
281

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab32$1,067,867
Humira(Cf) PenAdalimumab29$482,949
Humira PenAdalimumab41$379,928
Skyrizi On-BodyRisankizumab-Rzaa12$277,420
LinzessLinaclotide31$16,500
Mesalamine17$9,355
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates58$3,885
DexilantDexlansoprazole13$3,772
Lubiprostone30$2,186
Omeprazole81$1,155
Azathioprine22$1,108
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg25$586
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl50$479
Dicyclomine Hcl40$289
Pantoprazole Sodium39$251

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$357$1,067,86732 claims
AbbVieLinzess$842$16,50031 claims
Takeda Pharmaceuticals U.S.A., Inc.Dexilant$52$3,77213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 323 gastroenterology providers in Indiana.

Other gastroenterology in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →